Edecrin Tablet
NDC Package 25010-215-15
Package Information
Edecrin (ethacrynic acid) tablets is eDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.1.Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.2.Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.3.Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.4.Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. This formulation utilizes a tablet delivery system. Marketed by Bausch Health Us, Llc, this product is identified by NDC 25010-215 and is authorized under FDA application NDA016092.
Identification & Billing
- RxCUI: 1251903 - ethacrynic acid 25 MG Oral Tablet
- RxCUI: 1251905 - Edecrin 25 MG Oral Tablet
- RxCUI: 1251905 - ethacrynic acid 25 MG Oral Tablet [Edecrin]
- RxCUI: 211509 - Edecrin Sodium 50 MG Injection
- RxCUI: 211509 - ethacrynate sodium 50 MG Injection [Edecrin]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 25010 - Bausch Health Us, Llc
- 25010-215 - Edecrin
- 25010-215-15 - 100 TABLET in 1 BOTTLE
- 25010-215 - Edecrin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (25010-215). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 25010-215-15 identifies a specific commercial package of 100 tablet in 1 bottle of Edecrin, a human prescription drug labeled by Bausch Health Us, Llc. This tablet is formulated for oral use and contains ethacrynic acid as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch Health Us, Llc on January 10, 1967. The current certification is valid through December 31, 2027.
How is this Bausch Health Us, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 25010021515. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.